

**Appendix Table 1. Likelihood of First All-cause Hospitalization, Stroke/Systemic Embolism (SE)-related Hospitalization, and Major Bleeding (MB)-related Hospitalization During the Follow-up Among Nonvalvular Atrial Fibrillation Patients Treated with Other Oral Anticoagulants vs. Apixaban**

	<b>Hazard Ratio*</b>	<b>95% Confidence Interval</b>	<b>p-value</b>
<b>First All-cause Hospitalization</b>			
Rivaroxaban vs. Apixaban	1.35	1.26, 1.45	p<0.001
Dabigatran vs. Apixaban	1.07	0.94, 1.21	p=0.338
Warfarin vs. Apixaban	1.44	1.34, 1.54	p<0.001
<b>Stroke/SE-related Hospitalization</b>			
Rivaroxaban vs. Apixaban	1.38	1.05, 1.81	p=0.003
Dabigatran vs. Apixaban	1.28	0.83, 1.98	p=0.269
Warfarin vs. Apixaban	1.54	1.21, 1.95	p<0.001
<b>MB-related Hospitalization</b>			
Rivaroxaban vs. Apixaban	2.05	1.71, 2.44	p<0.001
Dabigatran vs. Apixaban	1.22	0.88, 1.70	p=0.232
Warfarin vs. Apixaban	1.88	1.58, 2.22	p<0.001

\*Hazard ratios do not include readmissions.